TGR BioSciences

TGR BioSciences, established in 2001 in Adelaide, Australia, operates as a specialized biotechnology firm focused on creating and producing immunoassays and related technologies. Initially a spin-out from the CRC for Tissue Growth and Repair, the company has become a key player in the life science, pharmaceutical, and diagnostic markets. A significant milestone in its history was the acquisition by Abcam plc in January 2020, integrating TGR into a global life science tools supplier. Prior to this, TGR was acquired by Expedeon AG in May 2018.

The company's business model is centered on the development and sale of proprietary assay kits and the licensing of its core technology. Its primary clients are pharmaceutical and biotechnology companies, as well as academic research laboratories that use these tools for drug discovery and cell biology research, particularly in areas like cancer, diabetes, and inflammatory diseases. Revenue is generated through the sale of its product lines, such as the SureFire® kits, and through licensing agreements for its CaptSure™ technology. These products are distributed globally through partners, including Revvity, Inc. and its parent company, Abcam.

TGR BioSciences' core offering is its patented CaptSure™ technology, an antibody immobilization system that enhances the speed, simplicity, and performance of immunoassays. This technology is the foundation for its flagship product range, SureFire® Ultra™, which includes over 500 assay kits for analyzing cellular phosphoproteins. These no-wash, bead-based assays are designed for high-throughput screening, providing a crucial toolbox for measuring endogenous signaling proteins. The CaptSure™ technology has also been adapted for multiplexing applications and is integral to Abcam's SimpleStep ELISA® range, which offers a faster workflow than conventional methods. The versatility of CaptSure™ allows its application across various formats, including bead-based assays, ELISA, lateral flow, and microfluidics, serving both life science and diagnostic markets.

Keywords: immunoassay technology, cell-based research, drug discovery, CaptSure technology, SureFire Ultra, antibody immobilization, phosphoprotein analysis, life sciences, high-throughput screening, ELISA kits, protein analysis, biotechnology, cell signaling, multiplexing assays, diagnostic technologies, Abcam subsidiary, Revvity distributor, Adelaide biotech, assay development, PC2 laboratory